Shortage of Anti-venins risks lives

From June of next year, Sanofi Pasteur's stock of anti-venin Fav-Afrique will be exhausted and no more will be produced by the company. The technology used to create the anti-venin will be used in rabies treatments, according to manufacturer Sanofi Pasteur.

“Fav-Afrique is no longer being manufactured so vulnerable farmers will lose their lives or limbs.” - Abdulrazaq Habib Bayero University

Treating bites from snakes like mambas, vipers and cobras just does not add up any more, Sanofi Pasteur said. But tens of thousands may die, unnecessarily, according to Médecins Sans Frontières (MSF) as it demanded action over the withdrawal of Fav-Afrique. MSF says there will be no alternatives to replace the Sanofi Pasteur treatment for at least two years and that five million people are bitten by snakes each year, 100,000 die and 400,000 are disabled or disfigured. Read more at The Independant Gallery photo by Drjones